| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CRTAM |
| Entrez GeneID | 56253 |
| clone | 1C11E10 |
| WB Predicted band size | 44.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD355 (AA: extra 18-287) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD355(TIGIT)抗体的参考文献示例(注：以下为假设性示例，实际文献请通过学术数据库查询)：
1. **文献名称**：*Targeting TIGIT in Cancer Immunotherapy: Mechanisms and Therapeutic Potential*
**作者**：Chauvin JM, Zarour HM
**摘要**：探讨抗CD355(TIGIT)抗体通过阻断TIGIT与CD155的相互作用，逆转T细胞耗竭并增强抗肿瘤免疫反应，联合PD-1/PD-L1抑制剂可提升疗效。
2. **文献名称**：*TIGIT as a Regulator of Autoimmunity and Tumor Immunity*
**作者**：Kurtulus S, Madi A
**摘要**：研究TIGIT在自身免疫疾病及肿瘤微环境中的作用，发现抗TIGIT抗体可调节调节性T细胞(Treg)活性，抑制过度免疫反应或增强抗肿瘤免疫。
3. **文献名称**：*Preclinical Development of a Novel Anti-TIGIT Antibody for Solid Tumors*
**作者**：Johnston RJ, et al.
**摘要**：报道一种新型抗TIGIT抗体的临床前研究，显示其单药或与抗PD-1联用可显著抑制小鼠肿瘤生长，机制涉及NK细胞和CD8+ T细胞激活。
4. **文献名称**：*TIGIT Blockade Rescues Exhausted T Cells in Chronic Viral Infection*
**作者**：Liu X, et al.
**摘要**：证明在慢性病毒感染模型中，抗TIGIT抗体可恢复耗竭T细胞的功能，提示其在慢性疾病和癌症中的治疗潜力。
**建议**：实际研究中可通过PubMed或Google Scholar检索关键词“TIGIT antibody”或“anti-CD355”获取最新文献。
CD355 antibody targets the CD355 antigen, also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), a cell-surface protein belonging to the TIM family. Initially identified in 2002. TIM-3 is expressed on immune cells, including activated T cells, regulatory T cells (Tregs), natural killer (NK) cells, and dendritic cells. It functions as an immune checkpoint regulator, modulating both adaptive and innate immune responses. TIM-3 interacts with ligands such as galectin-9. phosphatidylserine, and high-mobility group protein B1 (HMGB1), playing dual roles in immune activation and tolerance.
In pathological contexts, CD355/TIM-3 is implicated in immune exhaustion, particularly in chronic infections and cancers, where its overexpression on T cells correlates with suppressed anti-tumor immunity. Consequently, TIM-3 has emerged as a therapeutic target, with blocking antibodies explored in preclinical and clinical studies to rejuvenate immune responses. Anti-CD355 antibodies are also critical tools in research, enabling the detection of TIM-3 expression in flow cytometry, immunohistochemistry, and functional studies to dissect its role in autoimmune diseases, infectious diseases, and cancer immunotherapy.
The development of CD355 antibodies has advanced understanding of immune regulation, highlighting TIM-3 as a potential biomarker for disease progression and a candidate for combination therapies with other checkpoint inhibitors (e.g., anti-PD-1). However, its pleiotropic effects across cell types necessitate careful evaluation to balance therapeutic efficacy and immune-related adverse events.
×
